PCM
DNA icon

Penserra Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Penserra Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Buy
318
+66
+26% +$552 ﹤0.01% 995
2026
Q1 		$1K Buy
252
+6
+2% +$50 ﹤0.01% 1039
2025
Q4 		$2K Sell
246
-12,688
-98% -$137K ﹤0.01% 970
2025
Q3 		$188K Buy
12,934
+148
+1% +$1.77K ﹤0.01% 712
2025
Q2 		$143K Buy
12,786
+9,271
+264% +$71.8K ﹤0.01% 685
2025
Q1 		$20K Buy
3,515
+164
+5% +$1.67K ﹤0.01% 873
2024
Q4 		$32K Buy
3,351
+1,928
+135% +$16.5K ﹤0.01% 983
2024
Q3 		$11K Buy
1,423
+16
+1% +$160 ﹤0.01% 888
2024
Q2 		$19K Buy
1,407
+266
+23% +$7.94K ﹤0.01% 912
2024
Q1 		$52K Sell
1,141
-866
-43% -$44.8K ﹤0.01% 877
2023
Q4 		$134K Buy
2,007
+200
+11% +$12.2K ﹤0.01% 854
2023
Q3 		$130K Sell
1,807
-4,529
-71% -$362K ﹤0.01% 841
2023
Q2 		$470K Buy
6,336
+4,147
+189% +$245K 0.01% 540
2023
Q1 		$116K Sell
2,189
-133
-6% -$8.43K ﹤0.01% 759
2022
Q4 		$156K Buy
2,322
+1,757
+311% +$162K ﹤0.01% 734
2022
Q3 		$69K Sell
565
-1,029
-65% -$123K ﹤0.01% 778
2022
Q2 		$150K Sell
1,594
-784
-33% -$95.6K ﹤0.01% 710
2022
Q1 		$382K Buy
2,378
+383
+19% +$74.5K 0.01% 565
2021
Q4 		$661K Buy
1,995
+798
+67% +$379K 0.01% 468
2021
Q3 		$555K Buy
+1,197
New +$583K 0.01% 473

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Penserra Capital Management's DNA Position: Q2 2026 in Review

Penserra Capital Management increased its Ginkgo Bioworks (DNA) stake by 26% in Q2 2026, buying an estimated $552 and bringing the position to 318 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #995.

Penserra Capital Management first reported a position in DNA in Q3 2021 and has held it in 20 quarters since. The position peaked at $661K in Q4 2021. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Penserra Capital Management held 318 shares of Ginkgo Bioworks worth $3K as of Q2 2026.
  • Penserra Capital Management bought 66 Ginkgo Bioworks shares in Q2 2026, an estimated $552.
  • Ginkgo Bioworks made up ﹤0.01% of Penserra Capital Management's portfolio in Q2 2026, its #995 holding.
  • Penserra Capital Management first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 20 quarters since.
  • Penserra Capital Management's Ginkgo Bioworks position peaked at $661K in Q4 2021.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.